Atossa Therapeutics, Inc. (ATOS) Debt by Year
Atossa Therapeutics, Inc. held $41.3M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Atossa Therapeutics, Inc. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
ATOS Debt & Cash by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $49K+745.6% | $6K | N/A | N/A |
| Cash & Equivalents | $41.3M-41.9% | $71.1M-19.6% | $88.5M-20.2% | $110.9M-18.7% | $136.4M+244.8% | $39.6M+214.4% | $12.6M+21.2% | $10.4M+43.8% | $7.2M+138.4% | $3.0M-18.5% | $3.7M-56.3% | $8.5M+34.0% | $6.3M+267.6% | $1.7M-9.7% | $1.9M |
ATOS Debt & Cash by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q | Q2'2410-Q | Q1'2410-Q | Q4'2310-K | Q3'2310-Q |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash & Equivalents | $26.1M-54.9% | $31.7M-51.3% | $41.3M-41.9% | $51.8M-30.7% | $57.9M-27.2% | $65.1M-22.4% | $71.1M-19.6% | $74.8M-20.5% | $79.5M-20.0% | $84.0M-19.2% | $88.5M-20.2% | $94.0M-19.9% |
What long-term debt means
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date.
More Atossa Therapeutics, Inc. financials
Frequently Asked Questions
What was Atossa Therapeutics, Inc.'s long-term debt in fiscal year 2025?
Atossa Therapeutics, Inc. held $41.3M in cash and equivalents at the end of fiscal year 2025, and long-term debt is not reported for that period.
What does long-term debt mean on a financial statement?
Long-term debt is borrowing that falls due more than a year out, and the cash line beside it is what the company held on the same balance sheet date. This page lists what Atossa Therapeutics, Inc. (ATOS) reported on that line in every period on record.